EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Rash with Different Types of BCR-ABL Inhibitors in Chronic Myelogenous Leukemia: A Systematic Review and Meta-Analysis

Su Li iD, Tingwen Wang iD, Yu Zhong, Shuqi Dai

Future Oncology · 01.06.2023 · 19 (17) · 1215-1227

DOI: 10.2217/fon-2022-1008 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Future Oncology, online erschienen am 27.06.2023. Verfasst von Su Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, 110042, Liaoning Province, PR Ch…. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Exanthema, Antineoplastic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

A meta-analysis was conducted to systematically review the risks of all-grade as well as high-grade rash in chronic myelogenous leukemia (CML) patients using different types of BCR-ABL inhibitors.

Methods

Literature published between 2000 and April 2022 were searched using PubMed, Cochrane Library, Embase and ClinicalTrials.gov.

Results

A total of 12 studies were included for meta-analysis. The results showed that the incidence of all-grade or high-grade rash associated with new-generation BCR-ABL inhibitors had no significant difference compared with a standard dose of imatinib. Subgroup analysis suggested that, compared with imatinib, the incidence of all grades of rash was higher in the nilotinib, bosutinib and ponatinib groups.

Conclusion

For CML patients treated with nilotinib, bosutinib and ponatinib, the occurrence of skin toxicity should not be ignored.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveExanthemaAntineoplastic AgentsHumansImatinib MesylateFusion Proteins, bcr-ablProtein Kinase InhibitorsDrug Resistance, NeoplasmAniline CompoundsNitrilesQuinolines

Stichwörter der Autor:innen

BCR-ABL inhibitorsadverse reaction monitoringchronic myelogenous leukemiameta analysisskin-related adverse events

Substanzen

Imatinib MesylateFusion Proteins, bcr-ablProtein Kinase InhibitorsAntineoplastic AgentsbosutinibAniline CompoundsNitrilesQuinolines

Autor:innen und Institutionen

  • Department of Pharmacy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, 110042, Liaoning Province, PR China.
  • School of Basic Medicine & Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, 211198, PR China.

ORCID-Profile: Su Li, Tingwen Wang

Zitieren

APA

Li, S., Wang, T., Zhong, Y., & Dai, S. (2023). Rash with Different Types of BCR-ABL Inhibitors in Chronic Myelogenous Leukemia: A Systematic Review and Meta-Analysis. Future Oncology, 19(17), 1215-1227. https://doi.org/10.2217/fon-2022-1008

Vancouver

Li S, Wang T, Zhong Y, Dai S. Rash with Different Types of BCR-ABL Inhibitors in Chronic Myelogenous Leukemia: A Systematic Review and Meta-Analysis. Future Oncology. 2023;19(17):1215-1227. doi:10.2217/fon-2022-1008

BibTeX
@article{Li2023,
  author = {Li, Su and Wang, Tingwen and Zhong, Yu and Dai, Shuqi},
  title = {Rash with Different Types of BCR-ABL Inhibitors in Chronic Myelogenous Leukemia: A Systematic Review and Meta-Analysis},
  journal = {Future Oncology},
  year = {2023},
  volume = {19},
  number = {17},
  pages = {1215--1227},
  doi = {10.2217/fon-2022-1008}
}
Kostenlos starten →